Similarly, future clinical trials will examine the possibility that tumor vascularity, endothelial Tie-2 expression and tumor cell Ang-1 expression can serve as markers that can predict response to treatment, as indicated by our preclinical studies presented here. This evidence concerns the gene TEK and neoplasm.